Literature DB >> 31448457

Transaxillary endoscopic excision of benign breast tumors, early institution experience.

Mohamed A Mlees1, Waleed Y El-Sherpiny1, Hossam R Moussa1.   

Abstract

BACKGROUND AND AIM: Benign breast diseases are one of the most common diseases in females. An important goal in its treatment should be cosmesis, so a new minimally invasive technique has advanced. One of these techniques is the transaxillary endoscopic resection. The aim of this study was to assess the feasibility, safety, operative time, postoperative pain, hospital stay, and cosmetic outcome of this transaxillary approach.
METHODS: This study was carried out on 40 female patients presented with benign breast tumors in the surgical oncology unit at the General Surgery Department, Tanta University Hospital during the period from January 2018 to January 2019. The patients included in the study aged ≥18 years, had solitary or multiple benign breast tumors, located at any breast quadrant. The patients subjected to transaxillary endoscopic excision of the tumors.
RESULTS: The age of the patients ranged from 20 to 49 years with a mean age of 32 years. 60% of the lesions located in the upper half of the breast. Fibroadenoma was the most common finding in 80% of the patients, 60% of the patients had solitary tumor. The operative time ranged from 42 to 105 minutes with a mean of 61.4 minutes. 88.8% of the patients considered the cosmetic outcome excellent.
CONCLUSION: Endoscopic transaxillary excision of benign breast tumors is safe, feasible and has excellent cosmetic outcomes with high patient's satisfaction.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  benign breast tumors; cosmesis; endoscopic surgery; transaxillary approach

Mesh:

Year:  2019        PMID: 31448457     DOI: 10.1111/tbj.13498

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  1 in total

1.  Surgery for fibroadenoma arising from axillary accessory breast.

Authors:  Sung Ryul Lee
Journal:  BMC Womens Health       Date:  2021-04-07       Impact factor: 2.809

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.